The cicada COVID variant, officially designated as BA.3.2, is emerging as a significant concern in the United States due to its potential to evade immunity from vaccines and prior infections. As of March 2026, BA.3.2 has been detected in at least 25 states, raising alarms among health officials and the public alike.

First identified in South Africa in November 2024, BA.3.2 has rapidly spread, with reports indicating its presence in at least 23 countries. The variant is characterized by a staggering 70 to 75 mutations in its spike protein, which may allow it to circumvent the immune responses generated by existing vaccines. Andrew Pekosz, Ph.D., noted, “It has a lot of mutations that may cause it to look different to your immune system,” underscoring the variant’s potential threat.

Despite the alarming number of mutations, experts are cautious about the variant’s implications for disease severity. Dr. Adolfo García-Sastre stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” This observation provides a glimmer of hope amidst growing concerns, suggesting that while BA.3.2 may spread more easily, it does not necessarily lead to worse outcomes.

Current data shows that during the week ending March 21, 2026, BA.3.2 was detected in approximately 11% of wastewater samples in the U.S., indicating its increasing prevalence. The variant was first reported in the U.S. in June 2025, and since then, it has continued to spread, prompting the World Health Organization (WHO) to classify it as a “variant under monitoring” in December 2025.

Common symptoms associated with BA.3.2 include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms are consistent with those of previous COVID-19 variants, making it crucial for individuals to remain vigilant and seek testing if they experience any of these signs.

While the existing vaccines have shown effectiveness against severe illness from COVID-19, their efficacy against BA.3.2 remains a topic of investigation. Dr. Amesh A. Adalja remarked, “The existing vaccine is likely to protect against what matters most: serious illness,” providing some reassurance. However, the exact impact of BA.3.2 on disease severity is still unclear, and it is uncertain how effective current vaccines will be against this variant.

Details remain unconfirmed regarding the reasons for BA.3.2’s resurfacing and its implications for public health moving forward. As health authorities continue to monitor the situation, further developments are expected, and the public is encouraged to stay informed about the latest guidance from health officials.

The post Cicada COVID Variant BA.3.2 Raises Concerns in the United States appeared first on News Casino.

Before the emergence of the Cicada variant, the COVID-19 landscape in the UK was characterized by a gradual decline in cases and hospitalizations, largely attributed to the effectiveness of existing vaccines against earlier strains. The public health focus was on managing the remaining cases and ensuring vaccination coverage, with expectations that the pandemic was nearing an end. However, the detection of the Cicada variant has shifted this narrative significantly.

The decisive moment came when the Cicada variant, designated BA.3.2, was first identified in South Africa in November 2024. By March 2026, it had been reported in 24 countries, including the UK. The variant carries between 70 to 75 genetic changes in its spike protein, which has raised alarms among health officials. The variant’s rapid spread, making up approximately 30% of COVID-19 sequences reported in Denmark, Germany, and the Netherlands from late 2025 to early 2026, indicates its potential for widespread transmission.

The direct effects of the Cicada variant on public health are still unfolding. Symptoms associated with this variant include a particularly painful sore throat, fever, cough, fatigue, and nasal congestion. While there is no evidence that the Cicada variant causes more severe disease than previous variants, its ability to evade antibodies due to significant mutations poses a challenge for current vaccines. Experts have noted that the existing COVID-19 vaccine may be less effective against this variant.

Experts like Kyle B. Enfield have expressed concerns about the variant’s implications, stating, “Because it’s significantly different, the current COVID-19 vaccine may not be as effective.” Ian Budd highlighted the number of mutations, particularly on the virus’s spike protein, as a critical factor in its transmissibility. The CDC has warned that the Cicada strain “could be associated with seasonal increases in COVID-19 activity,” emphasizing the need for continued vigilance.

As of now, the UK has confirmed cases of the Cicada variant, and public health officials are monitoring the situation closely. The variant’s emergence comes at a time when the healthcare system is still recovering from the previous respiratory virus season, which saw an estimated 390,000 to 550,000 hospitalizations and 45,000 to 64,000 deaths. This context adds urgency to the response to the Cicada variant.

Despite the concerning mutations, experts have reassured the public that there is currently no sign that BA.3.2 is more dangerous than variants circulating in the winter of 2025-26. “There’s no sign so far that BA.3.2, nicknamed Cicada, is any more dangerous or causes more severe disease than the variants that were circulating in the winter of 2025-26,” stated Enfield. However, the uncertainty surrounding the long-term effectiveness of current vaccines against this variant remains a significant concern.

The Cicada variant is named after the insect that lies dormant for years before emerging, reflecting its ability to remain undetected before spreading. This metaphor underscores the challenges faced by public health officials in tracking and managing emerging variants. Details remain unconfirmed regarding the exact impact of the Cicada variant on public health due to limited genomic detection and surveillance capacities in many countries.

The post COVID 19 Cicada Variant UK: Understanding the New Developments appeared first on News Casino.

The BA.3.2 variant, nicknamed Cicada, is spreading quickly across the United States. As of February 2026, it has been detected in 23 countries and 29 U.S. states, raising alarms among health officials.

First identified in November 2024 in Africa, the BA.3.2 variant carries 70 to 75 genetic changes in its spike protein, which may affect how the virus interacts with the immune system. Experts are concerned that these mutations could allow the variant to evade immunity from previous infections or current vaccines. “Due to the high number of mutations, experts worry the variant may more easily bypass immunity from previous infections or current vaccines,” a health official stated.

Despite these concerns, there is currently no evidence that BA.3.2 causes more severe disease than previous variants. Emily Ronay Johnston, a virologist, noted, “There’s no sign so far that BA.3.2, nicknamed Cicada, is any more dangerous or causes more severe disease than the variants that were circulating in the winter of 2025-26.” This sentiment is echoed by other experts who emphasize that the majority of people infected with this variant report relatively mild illness, particularly among those who are vaccinated.

COVID-19 continues to pose a public health challenge, with the virus causing 300-500 deaths per week in the U.S. The first U.S. case of BA.3.2 was detected in a traveler in June 2025, indicating that the variant has been present for several months. While the variant may infect people more widely due to immune evasion, it is not considered more dangerous than its predecessors.

The historical context of the BA.3.2 variant is important, as it is descended from the Omicron variant, which emerged in late 2021. This lineage has been characterized by its rapid spread and mutations, leading to ongoing adjustments in public health responses and vaccine strategies.

As health officials continue to monitor the situation, the long-term impact of the BA.3.2 variant on public health remains unclear. The effectiveness of current vaccines against this variant is also not fully confirmed. Details remain unconfirmed.

In summary, while the Cicada variant is spreading rapidly and presents challenges due to its mutations, experts advise that there is no immediate cause for panic. The situation is being closely monitored as more data becomes available, and public health measures continue to adapt to the evolving landscape of COVID-19 variants.

The post Covid 19 cicada variant: COVID-19 Cicada Variant Spreads Rapidly Across the U.S. appeared first on News Casino.